TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15956995

Group type: COMPARATOR
Intervention: Antipsychotic-free patients
Number of subjects: 78

Group type: COMPARATOR
Intervention: Patients receiving atypical antipsychotics
Number of subjects: 78

Group type: COMPARATOR
Intervention: Patients receiving typical antipsychotics
Number of subjects: 78

Group type: COMPARATOR
Intervention: Patients with schizophrenia/schizophreniform disorder
Number of subjects: 78

Group type: COMPARATOR
Intervention: Patients with depression
Number of subjects: 78

Group type: COMPARATOR
Intervention: Patients with bipolar disorder
Number of subjects: 78

Group type: COMPARATOR
Intervention: Patients with other psychoses
Number of subjects: 78
Study: 12074399

Group type: EXPERIMENTAL
Intervention: Self-reported confidence to achieve and maintain an erection (IIEF)
Number of subjects: 799

Group type: EXPERIMENTAL
Intervention: Age and absence of sexual activity over the last 4 weeks
Number of subjects: 799

Group type: EXPERIMENTAL
Intervention: Health complaints, depression, IPSS score, absence of physical activity
Number of subjects: 799
Study: 10432132

Group type: EXPERIMENTAL
Intervention: Transdermal progesterone cream (20 mg progesterone daily)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Transdermal progesterone cream
Number of subjects: 102
Study: 8846247

Group type: EXPERIMENTAL
Intervention: 0.5% timolol drops
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo drops
Number of subjects: 37
Study: 1838075

Group type: EXPERIMENTAL
Intervention: 300 mg etodolac twice daily
Number of subjects: 61

Group type: COMPARATOR
Intervention: 500 mg naproxen twice daily
Number of subjects: 61
Study: 7452872

Group type: EXPERIMENTAL
Intervention: Whole-brain irradiation (2,000 rads in two weeks)
Number of subjects: 323

Group type: COMPARATOR
Intervention: No brain treatment (control)
Number of subjects: 323
Study: 30638797

Group type: EXPERIMENTAL
Intervention: qHPV vaccine
Number of subjects: 3006

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3006
Study: 29078810

Group type: EXPERIMENTAL
Intervention: Improved oxygen system (including standardized equipment package, training of staff, infrastructure support, quality improvement activities)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Pulse oximetry alone (Phase 1)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Full improved oxygen system package (Phase 2)
Number of subjects: 3
Study: 24736951

Group type: EXPERIMENTAL
Intervention: School-based preventive intervention (Rochester Resilience Project)
Number of subjects: 203
Study: 23408728

Group type: EXPERIMENTAL
Intervention: Naltrexone SR (32 mg/day) plus bupropion SR (360 mg/day)
Number of subjects: 1496

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1496
Study: 21861896

Group type: EXPERIMENTAL
Intervention: Hwangryunhaedoktang
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 19588525

Group type: EXPERIMENTAL
Intervention: 0.5 mg dutasteride once daily for 3 months (BPH)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 3.5 mg dutasteride once daily for 3 months (BPH)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 0.5 mg dutasteride once daily for 3 months (PCa)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 3.5 mg dutasteride once daily for 3 months (PCa)
Number of subjects: 25
Study: 17383309

Group type: EXPERIMENTAL
Intervention: Balloon-based distal protection
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 39
Study: 15102998

Group type: EXPERIMENTAL
Intervention: High-dose epinephrine (0.1 mg/kg)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Standard-dose epinephrine (0.01 mg/kg)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: High-dose epinephrine (0.1 mg/kg) in asphyxia cases
Number of subjects: 68

Group type: COMPARATOR
Intervention: Standard-dose epinephrine (0.01 mg/kg) in asphyxia cases
Number of subjects: 68
Study: 11452712

Group type: EXPERIMENTAL
Intervention: 30 mg extended-release (ER) buspirone tablets
Number of subjects: 18

Group type: COMPARATOR
Intervention: 15 mg immediate-release (IR) buspirone tablets
Number of subjects: 18
Study: 9741514

Group type: EXPERIMENTAL
Intervention: Atrial fibrillation
Number of subjects: 0
Study: 8067750

Group type: EXPERIMENTAL
Intervention: Antacid containing magnesium and aluminum hydroxide
Number of subjects: 10

Group type: COMPARATOR
Intervention: Pefloxacin without antacid
Number of subjects: 10
Study: 3134359

Group type: EXPERIMENTAL
Intervention: Indomethacin (25 mg three times daily for six weeks)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 201
Study: 29041997

Group type: EXPERIMENTAL
Intervention: Video
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Web-based module (WBM)
Number of subjects: 311

Group type: COMPARATOR
Intervention: Caregiver confidence
Number of subjects: 311

Group type: COMPARATOR
Intervention: School days missed
Number of subjects: 311

Group type: COMPARATOR
Intervention: Nights with difficulty sleeping
Number of subjects: 311

Group type: COMPARATOR
Intervention: Days before return to a normal diet
Number of subjects: 311

Group type: COMPARATOR
Intervention: Workdays missed
Number of subjects: 311
Study: 28219129

Group type: EXPERIMENTAL
Intervention: Sevoflurane (1.3 MAC for 40 min)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Desflurane (1.3 MAC for 40 min)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Propofol (3.5‐4.0 μg/ml target controlled infusion)
Number of subjects: 90
Study: 25770310

Group type: EXPERIMENTAL
Intervention: Low-frequency repetitive transcranial magnetic stimulation (rTMS)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 40
Study: 24329412

Group type: EXPERIMENTAL
Intervention: Character attributions
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Intention attributions
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Controllability attributions
Number of subjects: 212
Study: 20498215

Group type: EXPERIMENTAL
Intervention: ASspiMRI‐a (MRI inflammation score)
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: mSASSS (structural damage score)
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: BASMI (spinal mobility index)
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Disease duration < or = 3 years
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Disease duration > 3 years
Number of subjects: 214
Study: 19294776

Group type: EXPERIMENTAL
Intervention: Pharmaceutical-grade heroin under medical supervision
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 16178130

Group type: EXPERIMENTAL
Intervention: Cetylpyridinium chloride (CPC) mouthrinse
Number of subjects: 139

Group type: COMPARATOR
Intervention: Placebo rinse
Number of subjects: 139
Study: 14504152

Group type: EXPERIMENTAL
Intervention: Tetracaine patch (1 mg x cm(‐2), applied 30 min before venepuncture)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo patch (applied 30 min before venepuncture)
Number of subjects: 32
Study: 10922431

Group type: EXPERIMENTAL
Intervention: PTCA plus intracoronary stent placement
Number of subjects: 650

Group type: EXPERIMENTAL
Intervention: PTCA plus abciximab therapy
Number of subjects: 650

Group type: EXPERIMENTAL
Intervention: PTCA plus intracoronary stent placement plus abciximab therapy
Number of subjects: 650

Group type: COMPARATOR
Intervention: PTCA alone
Number of subjects: 650
Study: 8555493

Group type: EXPERIMENTAL
Intervention: Recombinant human interleukin-10 (rhIL-10)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 1907769

Group type: COMPARATOR
Intervention: Xeroform
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Duoderm
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Biobrane
Number of subjects: 30
Study: 7002524

Group type: EXPERIMENTAL
Intervention: Guanfacine (new antihypertensive drug)
Number of subjects: 14
Study: 30585438

Group type: EXPERIMENTAL
Intervention: Genetic polymorphism rs295137 (T allele) near SPATS2L
Number of subjects: 604

Group type: EXPERIMENTAL
Intervention: Genetic polymorphism rs2626393 (C allele) near ASB3
Number of subjects: 604
Study: 28904010

Group type: EXPERIMENTAL
Intervention: Cholecalciferol (vitamin D3) 4000 IU/day for 12 weeks
Number of subjects: 254

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 254
Study: 26714385

Group type: EXPERIMENTAL
Intervention: Tolvaptan 15 mg daily for 12 months
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (no tolvaptan)
Number of subjects: 24
Study: 24029881

Group type: EXPERIMENTAL
Intervention: E-learning tutorial
Number of subjects: 14
Study: 20506333

Group type: EXPERIMENTAL
Intervention: SES
Number of subjects: 904

Group type: COMPARATOR
Intervention: PES
Number of subjects: 904

Group type: EXPERIMENTAL
Intervention: SES (nondiabetic)
Number of subjects: 904

Group type: COMPARATOR
Intervention: PES (nondiabetic)
Number of subjects: 904

Group type: EXPERIMENTAL
Intervention: SES (diabetic)
Number of subjects: 904

Group type: COMPARATOR
Intervention: PES (diabetic)
Number of subjects: 904
Study: 19120322

Group type: EXPERIMENTAL
Intervention: Ear acupuncture
Number of subjects: 207

Group type: COMPARATOR
Intervention: Local anaesthetics
Number of subjects: 207
Study: 17714328

Group type: EXPERIMENTAL
Intervention: Virtual reality (VR) task
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control group (subjects with no history of neurological deficits)
Number of subjects: 8
Study: 15021220

Group type: EXPERIMENTAL
Intervention: argon laser trabeculoplasty plus betaxolol
Number of subjects: 255

Group type: COMPARATOR
Intervention: no immediate treatment
Number of subjects: 255
Study: 11500608

Group type: EXPERIMENTAL
Intervention: lansoprazole 60 mg once daily
Number of subjects: 62

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 62
Study: 10036122

Group type: EXPERIMENTAL
Intervention: Intraoperative pre-conditioning of laparoscopic gas with the Insuflow device
Number of subjects: 72

Group type: COMPARATOR
Intervention: Standard raw gas
Number of subjects: 72
Study: 7974373

Group type: EXPERIMENTAL
Intervention: CRVO patients
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Non-ischemic CRVO patients
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: CRVO patients with Lp(a) > 300 mg/l
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: CRVO patients with high Lp(a)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 40
Study: 2557950

Group type: EXPERIMENTAL
Intervention: PGA sutures
Number of subjects: 28

Group type: COMPARATOR
Intervention: PDS sutures
Number of subjects: 28
Study: 1157027

Group type: EXPERIMENTAL
Intervention: Postoperative chemotherapy with VAC for patients with embryonal carcinoma of the ovary
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chemotherapy with VAC for advanced embryonal carcinoma of the ovary
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined irradiation and chemotherapy with vincristine and actinomycin-D
Number of subjects: 0

Group type: COMPARATOR
Intervention: Postoperative irradiation therapy
Number of subjects: 0
Study: 31331789

Group type: EXPERIMENTAL
Intervention: Alirocumab (75 mg up to 150 mg every 2 weeks [COMBO I & II] or 150 mg every 2 weeks [LONG TERM])
Number of subjects: 4389

Group type: EXPERIMENTAL
Intervention: Alirocumab
Number of subjects: 4389

Group type: COMPARATOR
Intervention: Control (placebo [COMBO I and LONG TERM] or ezetimibe [COMBO II])
Number of subjects: 4389
Study: 27793576

Group type: EXPERIMENTAL
Intervention: Typical Beliefs Questionnaire (TBQ)
Number of subjects: 394
Study: 25783958

Group type: EXPERIMENTAL
Intervention: 60% ASiR dataset
Number of subjects: 40

Group type: COMPARATOR
Intervention: Filtered backprojection algorithm and ASiR (20%, 40%, 60%, and 80% blending)
Number of subjects: 40
Study: 22304242

Group type: COMPARATOR
Intervention: Dietary protein level at 28%
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Dietary protein level at 34%
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Dietary protein levels (28%, 30%, 32%, 34%, 36%, 38%)
Number of subjects: 60
Study: 22151475

Group type: EXPERIMENTAL
Intervention: Motion style acupuncture treatment (MSAT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonsteroidal anti‐inflammatory drug (NSAID) injection (diclofenac)
Number of subjects: 0
Study: 19107530

Group type: EXPERIMENTAL
Intervention: ABG alone
Number of subjects: 13

Group type: COMPARATOR
Intervention: ABG and PDLG
Number of subjects: 13
Study: 17694218

Group type: EXPERIMENTAL
Intervention: 20 mg of 1% ropivacaine gel (ropivacaine‐20)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 60 mg of 1% ropivacaine gel (ropivacaine‐60)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 20 mg of EMLA cream (EMLA‐20)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 60 mg of EMLA cream (EMLA‐60)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 20 mg of benzocaine gel (benzocaine‐20)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 60 mg of benzocaine gel (benzocaine‐60)
Number of subjects: 30
Study: 15154956

Group type: EXPERIMENTAL
Intervention: Group care
Number of subjects: 900

Group type: COMPARATOR
Intervention: Individual care
Number of subjects: 900
Study: 11799841

Group type: EXPERIMENTAL
Intervention: New bromazepam slow-release formulation
Number of subjects: 24

Group type: COMPARATOR
Intervention: Conventional bromazepam formulation
Number of subjects: 24
Study: 9516090

Group type: EXPERIMENTAL
Intervention: Dornase alfa 2.5 mg daily for 2 weeks via Medic‐Aid Durable SideStream nebulizer (MMAD 2.1 microm)
Number of subjects: 749

Group type: EXPERIMENTAL
Intervention: Dornase alfa 2.5 mg daily for 2 weeks via Hudson T Up‐draft nebulizer (MMAD 4.9 microm)
Number of subjects: 749

Group type: EXPERIMENTAL
Intervention: Dornase alfa via Medic‐Aid Durable SideStream nebulizer
Number of subjects: 749
Study: 8194024

Group type: EXPERIMENTAL
Intervention: Etoposide 25 mg/m2/day
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Etoposide 20 mg/m2/day
Number of subjects: 40
Study: 2721849

Group type: EXPERIMENTAL
Intervention: Sickness Impact Profile (SIP) completed by patients and physicians
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SIP reviewed by physicians prior to visit
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SIP usage in clinic
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SIP length
Number of subjects: 0
Study: 4394369

Group type: EXPERIMENTAL
Intervention: Oxprenolol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Practolol
Number of subjects: 0
Study: 31791323

Group type: EXPERIMENTAL
Intervention: Self-care intervention including a sexual health self-assessment with embedded clinical prediction tool predicting STI positivity and personalized messaging with key steps to lower risk for STIs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition including a self-assessment about water, soda and sugar sweetened beverage consumption and personalized messaging to meet recommended daily intake
Number of subjects: 0
Study: 29366739

Group type: EXPERIMENTAL
Intervention: RF-based microtenotomy
Number of subjects: 46

Group type: COMPARATOR
Intervention: Arthroscopic release
Number of subjects: 46
Study: 26660720

Group type: EXPERIMENTAL
Intervention: SRP + PDT (scaling and root planing combined with photodynamic therapy using methylene blue as a photosensitizer)
Number of subjects: 15

Group type: COMPARATOR
Intervention: SRP (scaling and root planing alone)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: SRP + PDT
Number of subjects: 15
Study: 23780898

Group type: EXPERIMENTAL
Intervention: Isotonic (IT: 110% of maximal isometric torque)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Isokinetic (IK: 120°/s)
Number of subjects: 16
Study: 21435821

Group type: EXPERIMENTAL
Intervention: Drain-clamping method using tranexamic acid and carbazochrome sodium sulfonate hydrate
Number of subjects: 100

Group type: COMPARATOR
Intervention: Drain-clamping with saline
Number of subjects: 100
Study: 19347928

Group type: EXPERIMENTAL
Intervention: 0.4% dexamethasone sodium phosphate iontophoresis
Number of subjects: 17

Group type: COMPARATOR
Intervention: Distilled water (control)
Number of subjects: 17
Study: 17883519

Group type: EXPERIMENTAL
Intervention: Zolmitriptan orally disintegrating tablets (ODT) 2.5 mg
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Zolmitriptan nasal spray 5 mg
Number of subjects: 48

Group type: COMPARATOR
Intervention: Conventional zolmitriptan tablets 2.5 mg
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Zolmitriptan (all formulations)
Number of subjects: 48
Study: 16284584

Group type: EXPERIMENTAL
Intervention: Transdermal fentanyl (TDF)
Number of subjects: 680

Group type: COMPARATOR
Intervention: Sustained release morphine (SRM)
Number of subjects: 680
Study: 12139679

Group type: EXPERIMENTAL
Intervention: 0.1% methylprednisolone aceponate milk (MPA)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 0.1% hydrocortisone 17‐butyrate emulsion (HCB)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Untreated area
Number of subjects: 24
Study: 9464749

Group type: EXPERIMENTAL
Intervention: Hypertonic saline (HTS)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Lactated Ringer's solution (LRS)
Number of subjects: 34
Study: 7716196

Group type: EXPERIMENTAL
Intervention: Tyrosine (100 mg/kg of body weight)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 2757879

Group type: COMPARATOR
Intervention: Flosequinan
Number of subjects: 12

Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 12
Study: 779751

Group type: EXPERIMENTAL
Intervention: Oral terbutaline (5 mg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Aerosol fenoterol (400 micrograms)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 31064877

Group type: EXPERIMENTAL
Intervention: Police body-worn cameras (BWCs)
Number of subjects: 2224
Study: 29798542

Group type: EXPERIMENTAL
Intervention: Lateral retinacular release
Number of subjects: 126

Group type: COMPARATOR
Intervention: Control (no lateral retinacular release)
Number of subjects: 126
Study: 25385408

Group type: EXPERIMENTAL
Intervention: Group fitness class for pregnant women, 60 min class with 40 min endurance training and 20 min strength training, performed at least twice per week for a minimum of 12 weeks
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Group fitness class for pregnant women
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 105
Study: 23933545

Group type: EXPERIMENTAL
Intervention: ivabradine 7.5 mg twice a day
Number of subjects: 275

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 275
Study: 22136094

Group type: EXPERIMENTAL
Intervention: ER d‐MPH (10, 20, 25‐30 mg)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: ER MAS (10, 20, 25‐30 mg)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo (randomized within each drug period)
Number of subjects: 56
Study: 18583015

Group type: EXPERIMENTAL
Intervention: Video-calls
Number of subjects: 6

Group type: COMPARATOR
Intervention: Traditional phone calls
Number of subjects: 6
Study: 16780389

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bare metal stents (BMS)
Number of subjects: 0
Study: 14518664

Group type: EXPERIMENTAL
Intervention: Ticlopidine alone (200 mg daily)
Number of subjects: 276

Group type: COMPARATOR
Intervention: Ticlopidine plus aspirin (100 mg daily plus 81 mg daily)
Number of subjects: 276
Study: 11193512

Group type: EXPERIMENTAL
Intervention: Injection speed of 0.2 ml/sec
Number of subjects: 100

Group type: COMPARATOR
Intervention: Injection speed of 0.03 ml/sec
Number of subjects: 100
Study: 9178459

Group type: EXPERIMENTAL
Intervention: Inactivated hepatitis A vaccine, 180 ELISA units per dose
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Inactivated hepatitis A vaccine, 360 ELISA units per dose
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Inactivated hepatitis A vaccine, 720 ELISA units per dose
Number of subjects: 110
Study: 1488568

Group type: EXPERIMENTAL
Intervention: Fenoterol/ipratropium bromide combination (Berodual) inhaled as a dry powder
Number of subjects: 38

Group type: COMPARATOR
Intervention: Fenoterol/ipratropium bromide combination (Berodual) by metered dose inhaler (MDI)
Number of subjects: 38
Study: 2859653

Group type: EXPERIMENTAL
Intervention: 40 mg famotidine in the evening
Number of subjects: 131

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 131
Study: 31302868

Group type: EXPERIMENTAL
Intervention: Fosfomycin
Number of subjects: 608

Group type: COMPARATOR
Intervention: Control (non-exposed cohort)
Number of subjects: 608
Study: 30219062

Group type: EXPERIMENTAL
Intervention: High zinc biofortified wheat flour (HZn, 30 ppm zinc daily)
Number of subjects: 6005
Study: 27454662

Group type: EXPERIMENTAL
Intervention: ETORICOX-PREOP group received etoricoxib 120 mg orally 1 h before surgery
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: ETORICOX-POSTOP group received etoricoxib 120 mg at the end of surgery
Number of subjects: 165

Group type: COMPARATOR
Intervention: PLACEBO group received placebo pills
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: ETORICOX-PREOP group
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: ETORICOX-POSTOP group
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 165
Study: 23811290

Group type: EXPERIMENTAL
Intervention: 10-ppm nanoscale silver particle solution
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 32-ppm nanoscale silver particle solution
Number of subjects: 60
Study: 23011002

Group type: EXPERIMENTAL
Intervention: Yellow spectacle lenses worn for 3 months
Number of subjects: 82

Group type: COMPARATOR
Intervention: Without yellow spectacle lenses (control group)
Number of subjects: 82
Study: 20835574

Group type: EXPERIMENTAL
Intervention: 1% NaOCl
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 1% NaOCl followed by 17% EDTA
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (no irrigating solution)
Number of subjects: 30
Study: 18060675

Group type: EXPERIMENTAL
Intervention: 3 g of n‐3 PUFAs (EPA and DHA)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Soybean oil (placebo)
Number of subjects: 22
Study: 15990633

Group type: EXPERIMENTAL
Intervention: Enteral glutamine supplementation (0.3 g/kg per day)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control (isonitrogenous placebo supplementation with alanine)
Number of subjects: 102
Study: 12969111

Group type: EXPERIMENTAL
Intervention: HES 130/0.4
Number of subjects: 60

Group type: COMPARATOR
Intervention: HES 200/0.5
Number of subjects: 60